![Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33]()
Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33Azoitei, N.; Hoffmann, C. M.; Ellegast, J. M.; Ball, C. R.; Obermayer, K.; Gossele, U.; Koch, B.; Faber, K.; Genze, F.; Schrader, M.; Kestler, H. A.; Dohner, H.; Chiosis, G.; Glimm, H.; Frohling, S.; Scholl, C. · Journal of Experimental Medicine · 2012